<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>阿斯利康Covid疫苗数据的严重疑问Serious Doubts Surround AstraZeneca Covid Vaccine Data</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">Serious Doubts Surround AstraZeneca Covid Vaccine Data<br/>阿斯利康Covid疫苗数据的严重疑问</h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-11-26 03:01:39</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2020/11/14c00597748cee3f5c3331595f706c2e.jpg"><img src="http://img2.diglog.com/img/2020/11/14c00597748cee3f5c3331595f706c2e.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>The makers of a third coronavirus vaccine  announced positive results in clinical trials on Monday, setting off yet another round of excited news reports. This one, produced by a partnership between a University of Oxford research institute, its spinout company  Vaccitech, and the pharmaceutical company AstraZeneca, does not need to be stored at freezing temperatures and would be cheaper and easier to produce than the high-efficacy vaccines produced by BioNTech-Pfizer and Moderna. Indeed, according to an  initial write-up in  The  New York Times, Oxford-AstraZeneca’s is “expected to be relied upon heavily across the globe, to help curb a pandemic that has killed more than 1.3 million people.”</p><p>第三种冠状病毒疫苗的生产商周一在临床试验中宣布了积极结果，掀起了又一轮激动人心的新闻报道。这是由牛津大学研究机构，其衍生公司Vaccitech和制药公司AstraZeneca之间的合作伙伴关系生产的，不需要保存在冷冻温度下，并且比生产的高效疫苗更便宜，更容易生产由BioNTech-Pfizer和Moderna。确实，根据《纽约时报》的最初报道，牛津阿斯利康的“预计将在全球范围内得到广泛依赖，以帮助遏制已经造成超过130万人死亡的大流行。”</p><p> Sounds like great news, right? Monday’s press release from AstraZeneca presents “ convincing evidence that [the vaccine] works,” said  Science. But not everyone has been convinced. The price of AstraZeneca’s shares  actually dropped on the news, and an analysis from an investment bank concluded, “We believe that this product will never be licensed in the US.” Over at  STAT News,  Anthony Fauci cautioned that we’ll need to see more data before coming to a conclusion. The skeptics have strong reasons to be concerned: This week’s “ promising” results are nothing like the  others that we’ve been hearing about in November—and the claims that have been drawn from them are based on very shaky science.</p><p> 听起来像个好消息，对不对？周一，阿斯利康的新闻稿提供了“令人信服的证据，证明[疫苗]有效”。但是并不是每个人都被说服。该消息传出后，阿斯利康的股价实际上下跌了，投资银行的分析得出的结论是：“我们相信该产品永远不会在美国获得许可。” STAT News的Anthony Fauci告诫我们，在得出结论之前，我们需要查看更多数据。持怀疑态度的人有充分的理由要担心：本周的“有希望的”结果与我们在11月听到的其他结果完全不同，并且从他们那里得出的主张都是基于不稳定的科学。</p><p>  The problems start with the fact that Monday’s announcement did not present results from a single, large-scale,  Phase 3 clinical trial, as was the case for earlier bulletins about the BNT-Pfizer and Moderna vaccines. Instead, Oxford-AstraZeneca’s data came out of two separate studies: one in the UK that  began in May, and another in Brazil, which got started  at the end of June. These two studies were substantially different from one another: They didn’t have standardized dosing schemes across the trials, for one thing, nor did they provide the same “control” injections to volunteers who were not getting the experimental Covid vaccine. The fact that they may have had to combine data from two trials in order to get a strong enough result raises the first red flag.</p><p>  问题开始于一个事实，即周一的公告没有提供单一的大规模3期临床试验的结果，就象早先有关BNT-Pfizer和Moderna疫苗的公告一样。相反，牛津-阿斯利康的数据来自两项单独的研究：一项是在5月开始的英国研究，另一项是在6月底开始的巴西研究。这两项研究彼此之间有很大的不同：一方面，它们没有标准化的给药方案，也没有为没有获得Covid实验性疫苗的志愿者提供相同的“对照”注射。为了获得足够强的结果，他们可能必须合并两个试验的数据，这一事实引发了第一个危险信号。</p><p>  Consider that leading vaccine makers—including AstraZeneca—issued a  scientific-rigor-and-integrity pledge back in September, in which they promised to submit their products for approval or emergency use authorization only “after demonstrating safety and efficacy through a Phase 3 clinical study that is designed and conducted to meet requirements of expert regulatory authorities such as FDA.” Note the wording here: These companies did not suggest that they might claim to have demonstrated efficacy through multiple, distinct clinical studies, combined together to get enough data. They said they would use  a Phase 3 study—as in,  one big one. Yet AstraZeneca has already applied on the basis of this data for approval  in Canada, and has plans to do the same in Britain, Europe and Brazil. The company also says it will use the data to apply for emergency use authorization  in the US.</p><p>  考虑到领先的疫苗生产商（包括阿斯利康在内）在9月份就发布了科学严谨和完整的承诺，在该承诺中，他们承诺只有在“通过3期临床研究证明其安全性和有效性之后，才将产品提交批准或紧急使用授权”旨在满足诸如FDA之类的专家监管机构的要求。”请注意此处的措辞：这些公司并未暗示他们可能声称已通过多个独特的临床研究证明其功效，并结合在一起以获取足够的数据。他们说，他们将使用第3阶段的研究，例如一项大型研究。然而，阿斯利康已经根据这些数据在加拿大申请批准，并计划在英国，欧洲和巴西也这样做。该公司还表示，将使用这些数据在美国申请紧急使用授权。</p><p>  The  Food and Drug Administration’s guidance for Covid-19 vaccines does allow for emergency use authorization based on interim analyses, but the same document says this must be supported by a minimum level of vaccine efficacy “for a placebo-controlled efficacy trial.” Again: it refers to  a trial. That is exactly what BNT-Pfizer and Moderna did. Both released the FDA-approved blueprints for their trials—called trial protocols—weeks ahead of time, with details of the calculations and statistical rules that they’d use to determine when to perform an interim analysis and how much certainty could be attached to those results. When BNT-Pfizer’s discussions with the FDA led to changes in this plan, BNT-Pfizer explained why, and released an updated protocol. That’s scientific rigor, and it matters a lot. When a vaccine-maker specifies the rules of the game before the results start coming in, we can check their work and be confident in what they tell us at the end. We can make sure they haven’t cherry-picked the data.</p><p>  美国食品药品监督管理局（FDA）的Covid-19疫苗指南确实允许根据临时分析进行紧急使用授权，但同一文件说，这必须由“针对安慰剂对照功效试验”的最低疫苗功效水平来支持。再次：它指的是审判。这正是BNT-Pfizer和Moderna所做的。两家公司都提前数周发布了FDA批准的试验蓝图（称为试验方案），并提供了用于确定何时进行中期分析的计算和统计规则的详细信息，以及可以赋予这些分析多少确定性的信息。结果。当BNT-Pfizer与FDA的讨论导致该计划的变更时，BNT-Pfizer解释了原因，并发布了更新的协议。这是科学严谨的，非常重要。当疫苗生产商在结果开始出现之前指定游戏规则时，我们可以检查他们的工作，并对他们最后告诉我们的内容充满信心。我们可以确保他们没有挑剔的数据。</p><p>  The Oxford-AstraZeneca story is very different, though. Presumably, neither of the two trials from which they combined data could have provided a clear answer on the vaccine’s efficacy on its own. To make things worse, Oxford-AstraZeneca reported only the results for certain subgroups of people within each one. (For perspective on this: The two subgroups chosen leave out perhaps half the people in the Brazilian trial.) Meanwhile, one of their key claims is that giving half a dose of the vaccine on the first injection, followed by a standard dose on the second one, led to better outcomes—but neither of these trials had been designed to test this hypothesis. In fact, it’s since emerged that the half-dose/full-dose option started out as  a mistake, and one that was only caught when some people in the study didn’t have the usual high rate of adverse effects.</p><p>  但是，牛津大学与阿斯利康的故事却大不相同。据推测，两项数据相结合的试验都没有单独给出疫苗功效的明确答案。更糟糕的是，牛津阿斯利康只报告了每个人中某些特定人群的结果。 （从这个角度来看：在巴西的试验中，选择的两个亚组可能没有一半的人参加。）同时，他们的主要主张之一是，在第一次注射时先给一半剂量的疫苗，然后在标准剂量下给标准剂量的疫苗。第二，导致更好的结果-但这些试验均未设计为检验该假设。实际上，从那时起就出现了半剂量/全剂量的选择开始是一个错误，而只有当研究中的某些人没有通常的高不良反应率时，这种选择才被发现。</p><p>  There were other dosing issues, too, that haven’t been explained even though dosing is the centerpiece of the press release. There are many different regimens in these trials—the UK study has more than two dozen arms, meaning the volunteers were divided into that many groups according to age and how much of the vaccine would be administered and when. The doses are measured by the number of altered viral particles they contain, and the developers decided that the standard dose would be 5 x 1010 viral particles. But for many of those arms in the UK trial—as well as everyone who got the vaccine in the Brazilian trial—publicly available  trial information shows that the standard dose could be between 3.5 and 6.5 × 1010 viral particles. The lower end of that range isn’t far off from a half-dose.</p><p>  即使是新闻发布的重点，也存在其他未解决的配量问题。这些试验中有许多不同的方案-英国的研究有两个以上的小组，这意味着根据年龄，将注射多少疫苗以及何时注射，志愿者被分为许多组。剂量由它们包含的改变的病毒颗粒数来衡量，开发人员决定标准剂量为5 x 1010病毒颗粒。但是对于英国试验中的许多武器，以及在巴西试验中获得疫苗的每个人，公开可用的试验信息显示，标准剂量可能在3.5至6.5××1010病毒颗粒之间。该范围的下限与半剂量剂量相距不远。</p><p>  How did Oxford-AstraZeneca end up with this patched-together analysis instead of data from a single, large trial? After all, this vaccine went into Phase 3 testing before either BNT-PFizer’s or Moderna’s did. But in the UK, where that testing started, the Covid-19 outbreak happened to be receding. That meant results would be coming in very slowly.</p><p>牛津大学阿斯利康公司如何最终完成了这种拼凑在一起的分析，而不是一次大型试验的数据？毕竟，这种疫苗先于BNT-PFizer或Moderna进行了第三阶段测试。但是在开始进行这项测试的英国，Covid-19爆发正逐渐消退。这意味着结果将会非常缓慢。</p><p> A  month later, a second Phase 3  trial for the vaccine started in Brazil. That one was for healthcare workers, for whom the risk of being exposed to Covid was far higher than it was for the people in the UK trial. But the two trials had other substantive differences. In the UK, for example, the volunteers who did not get the experimental Covid vaccine were injected with meningococcal vaccine; in Brazil, those in the comparison group were given a saline injection as a placebo.</p><p> 一个月后，该疫苗的第二期3期试验在巴西开始。那是针对医护人员的，他们接触Covid的风险远高于英国试验中的人。但是，这两项审判还有其他实质性差异。例如在英国，未接种实验性Covid疫苗的志愿者被注射了脑膜炎球菌疫苗。在巴西，对照组的人被注射了盐水作为安慰剂。</p><p> Meanwhile,  BNT-Pfizer and  Moderna began Phase 3 trials for their coronavirus vaccines on the same day in July: Both planned to include 30,000 volunteers at the time, and both trial plans were approved by the FDA. Oxford-AstraZeneca then  announced they, too, would run a 30,000-person trial in the US.</p><p> 同时，BNT-Pfizer和Moderna于7月的同一天开始了他们的冠状病毒疫苗的3期试验：两者都计划当时包括30,000名志愿者，并且两个试验计划均已获得FDA的批准。牛津阿斯利康公司随后宣布，他们也将在美国进行30000人的审判。</p><p> But that research on the Oxford-AstraZeneca vaccine quickly fell behind the others’. The US trial was approved by the FDA, but it didn’t start recruiting people until the  end of August; and just a week later, it was  put on hold so the FDA could investigate  a serious adverse event in the UK trial. It wasn’t clear what caused the volunteer to get sick, but the FDA did not give the all-clear for Oxford-AstraZeneca’s US trial to resume until  Oct. 23. By then  the protocol for the trial had been publicly released. It says the plan is to inject the vaccine in two standard doses, a month apart; and two people will be vaccinated for every one who gets a placebo saline injection.</p><p> 但是，有关牛津-阿斯利康疫苗的研究很快落后于其他研究。这项美国试验已获得FDA批准，但直到8月底才开始招募人员。仅仅一周之后，它就被搁置了，以便FDA可以调查英国试验中的严重不良事件。目前尚不清楚是什么原因导致志愿者生病，但FDA并未对牛津-阿斯利康的美国临床试验给予完全批准，直到10月23日才恢复。它说计划是以两个标准剂量注射疫苗，间隔一个月。每注射一次安慰剂盐水注射疫苗的人就会接种两人。</p><p> So here we are at the end of November. BNT-Pfizer and Moderna have offered up a masterclass in how to do major vaccine trials quickly in a pandemic, while Oxford-AstraZeneca has, for the moment, only an assortment of smaller ones ready to look at.</p><p> 因此，我们到了11月底。 BNT-Pfizer和Moderna提供了如何在大流行中快速进行主要疫苗试验的大师班，而牛津-阿斯利康目前仅提供各种较小的疫苗可供研究。</p><p>   But wait, more red flags! Last week, Oxford-AstraZeneca  published some results from earlier in the development of the UK trial. That paper included a trial protocol for the UK study, attached as an  appendix. Deep in that document, and apparently overlooked by reporters and commentators, was an eyebrow-raising suggestion: Under a section marked “Interim and primary analyses of the primary outcome,” the trialists outline a plan to combine and analyze data from four clinical trials (only half of which are Phase 3), carried out in different ways on three different continents. The plan, they wrote, was to pull out results only for the people across these four trials who had gotten &#34;two standard-dose vaccines,&#34; and then pool those together for what&#39;s called a  meta-analysis.</p><p>   但是，等等，更多的危险信号！上周，牛津大学阿斯利康公司发布了英国试验发展早期的一些结果。该文件包括附录中的英国研究的试验方案。在该文件的深处，显然是被记者和评论员所忽略的，这是一个令人毛骨悚然的建议：在标有“主要结果的中期和主要分析”的部分下，试验者概述了一项计划，以合并和分析来自四个临床试验的数据（在第三阶段中，只有一半是在三个不同的大陆以不同的方式进行的。他们写道，该计划的目的是仅针对这四项获得“两种标准剂量疫苗”的试验的人群得出结果，然后将它们汇总在一起进行所谓的荟萃分析。</p><p>  The appendix doesn’t say when this became the plan. We don’t even know if the Oxford-AstraZeneca team followed it. In fact, it’s impossible to know, at this point, just how many analyses these researchers have run, and on which data. That’s a scientific red flag with flashing lights. (Again it’s useful to compare this work to the BNT-Pfizer and Moderna trials, where the analyses were clearly spelled out ahead of time for everyone to see.) All we know for sure is that on Monday, Oxford-AstraZeneca  announced results of a different interim analysis that included only volunteers from the two trials in the UK and Brazil. As we’ve seen, this analysis was not limited to the people who got two standard doses of the vaccine.</p><p>  附录没有说明何时成为计划。我们甚至都不知道牛津阿斯利康团队是否遵循了这一要求。实际上，目前还无法知道这些研究人员进行了多少分析以及基于哪些数据。这是科学的红旗，上面有闪烁的灯光。 （再次将这项工作与BNT-Pfizer和Moderna试验进行比较是很有用的，因为在这些试验中清楚地列出了分析结果，以便所有人都可以看到。）我们可以确定的是，周一，牛津-阿斯利康宣布了不同的中期分析，仅包括来自英国和巴西两项试验的志愿者。如我们所见，该分析不仅限于接种了两种标准剂量疫苗的人群。</p><p>  There are other problems, too. In the press release, Oxford-AstraZeneca reports that two of the dosing regimens “demonstrated efficacy.” Presumably, none of the others did, but they didn’t give specifics. Of the only two regimens they reported, one (the mistaken first half-dose, followed by a full dose at least a month later) came in at 90 percent, and the other (two standard doses at least a month apart) achieved only 62 percent efficacy. You’ll see reports that the vaccine had  70 percent efficacy, on average; but that’s un-knowable, because we only have numbers on these two regimens, as opposed to everyone in the trials—and how they arrived at those percentages isn’t explained. As far as we know, some of this analysis could hinge on data from just a few sick people. That means the findings  could be a coincidence, or they could be biased by other factors. For example, it has  since been revealed that the people who received an initial half-dose—and for whom the vaccine was said to have 90-percent efficacy—included no one over the age of 55. That was not the case for the standard-dosing group, however, where the reported efficacy was 62 percent. This demographic difference could be more important than the change to the size of the first dose.</p><p>还有其他问题。牛津阿斯利康公司在新闻稿中报道说，两种给药方案“证明了疗效”。大概其他人都没有，但是他们没有给出具体细节。他们报告的仅有的两种方案中，一种方案（错误的前半剂量，然后在至少一个月后进行全剂量）的使用率为90％，另一种方案（相隔至少一个月的两次标准剂量）仅达到62％功效百分比。您会看到有关该疫苗的平均功效为70％的报告；但这是不知道的，因为我们只有这两种方案的数字，而不是试验中的每个人，而且没有说明它们如何得出这些百分比。据我们所知，某些分析可能仅依赖于少数病人的数据。这意味着发现可能是巧合，或者可能因其他因素而有偏差。例如，此后发现，最初接受半剂量的人（据称对他们的疫苗具有90％的功效）不包括55岁以上的人。标准不是这种情况。剂量组，但报告的疗效为62％。这种人口统计学差异可能比更改第一剂剂量更重要。</p><p>  That’s not the end of the problems. Overall, the Oxford-AstraZeneca trials appear to include relatively few participants over the age of 55, even though this group is especially vulnerable to Covid-19. (People over 55 were not originally eligible to join the Brazilian trial at all.) Compare that to BNT-Pfizer’s trial, where  41 percent of the volunteers were over 55. The Oxford-AstraZeneca vaccine also seems to produce  relatively high rates of adverse events. If you want to dig further into this vaccine’s story and issues, I’ve laid out a more detailed rundown of the Oxford-AstraZeneca trials and sources  here.</p><p>  这还不是问题的结局。总体而言，牛津-阿斯利康的试验似乎只包括了相对较少的55岁以上的参与者，尽管该人群特别容易受到Covid-19的攻击。 （55岁以上的人群最初根本没有资格参加巴西试验。）与BNT-Pfizer的试验相比，该试验有41％的志愿者超过55岁。牛津-阿斯利康疫苗似乎也产生了较高的不良反应率。如果您想进一步研究这种疫苗的故事和问题，我在这里列出了更详细的牛津阿斯利康试验和来源清单。</p><p> Now it’s over to drug regulatory agencies around the world. They have to make a decision about this vaccine that was once ahead of the pack, but for which there are still no reliable and rigorous results from a single, large phase 3 trial. If anything short of that standard is accepted for this vaccine, it will be easy to stoke already widespread  fears about corners being cut. A loss of trust would affect more than this one vaccine.</p><p> 现在已经移交给世界各地的药品监管机构。他们必须对这种疫苗做出决定，而这种决定曾经是领先者，但是对于一次大型的3期临床试验，仍然没有可靠而严格的结果。如果这种疫苗接受了任何不符合该标准的东西，很容易引起人们对已经被削减的普遍担忧。失去信任将影响的不仅仅是这一种疫苗。</p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.wired.com/story/the-astrazeneca-covid-vaccine-data-isnt-up-to-snuff/">https://www.wired.com/story/the-astrazeneca-covid-vaccine-data-isnt-up-to-snuff/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/covid/">#covid</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/surround/">#surround</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>